Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variants

16 Mar 2023

Abstract excerpt

Abstract Emerging SARS-CoV-2 variants, particularly the Omicron variant and its sublineages, continually threaten the global public health. Small molecule antivirals are an effective treatment strategy to fight against the virus. However, the first-generation antivirals either show limited clinical efficacy and/or have some defects in pharmacokinetic (PK) properties. Moreover, with increased use of these drugs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36928316
DOI: 10.1038/s41392-023-01392-w

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new generation Mpro inhibitor with potent activity against SARS-CoV-2 Omicron variantsPMID 36928316Read ↗

An oral non-covalent non-peptidic inhibitor of SARS-CoV-2 Mpro ameliorates viral replication and pathogenesis in vivoSemantic proximity Read ↗

Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative StudySemantic proximity Read ↗

Evaluation of antiviral drugs against newly emerged SARS-CoV-2 Omicron subvariantsSemantic proximity Read ↗

Recent advances in small-molecular therapeutics for COVID-19Semantic proximity Read ↗

Oral administration of S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and accelerates recovery from clinical aspects of COVID-19Semantic proximity Read ↗

Novel Antiviral Therapeutic Against SARS-CoV-2 and its Variants: Recent Developments and Future PerspectivesSemantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231Semantic proximity Read ↗

Novel inhibitors against COVID-19 main protease suppressed viral infectionSemantic proximity Read ↗

Structural basis for the inhibition of coronaviral main proteases by PF-00835231.Semantic proximity Read ↗

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read ↗

Nanomolar anti-SARS-CoV-2 Omicron activity of the host-directed TMPRSS2 inhibitor N-0385 and synergistic action with direct-acting antiviralsSemantic proximity Read ↗

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment StrategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.